Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
1(8%)
Results Posted
25%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
1
8%
Ph not_applicable
11
85%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
1(8.3%)
N/ANon-phased studies
11(91.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(8)
Terminated(1)
Other(3)

Detailed Status

Completed8
unknown3
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
88.9%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (8.3%)
N/A11 (91.7%)

Trials by Status

unknown323%
active_not_recruiting18%
completed862%
terminated18%

Recent Activity

1 active trials
Showing 5 of 13
terminatednot_applicable

Blue Light Photobiomodulation Therapy on Neuroischemic Patients

NCT04831606
active_not_recruitingnot_applicable

A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot

NCT04564443
completednot_applicable

Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

NCT03398538
completednot_applicable

Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers

NCT02331147
completednot_applicable

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04831606Not Applicable

Blue Light Photobiomodulation Therapy on Neuroischemic Patients

Terminated
NCT04564443Not Applicable

A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot

Active Not Recruiting
NCT03398538Not Applicable

Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

Completed
NCT02331147Not Applicable

Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers

Completed
NCT04040426Not Applicable

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

Completed
NCT02870816Not Applicable

Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers

Completed
NCT03881254Not Applicable

SkinTE™ in the Treatment of Diabetic Foot Wounds

Completed
NCT03230175Phase 2

Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

Completed
NCT01921491Not Applicable

DHACM vs Other Commercially Available Treatments

Completed
NCT03615807Not Applicable

Less Infections for the Diabetic Foot

Completed
NCT02813161

The Diabetic Foot Ulcer Registry

Unknown
NCT02399826Not Applicable

Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers

Unknown
NCT00500175Not Applicable

Novel Home Care Device for High-Risk Diabetic Patients

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
13